Strategic Intelligence: Immuno-oncology (2025)

Description

This report includes coverage of immuno-oncology overview, trends, leading marketed and pipeline products, market analysis, regulatory landscape and market access, opportunities, challenges, and unmet needs, commercial assessment - major current and future players in the immuno-oncology field.

The global market value for bispecific antibodies, cancer vaccines, checkpoint modulators, cell therapies, cytokines, and oncolytic viruses increased from $10.4 billion in 2014 to $74 billion in 2024.

This growth trajectory is expected to continue, with the total market reaching $186 billion by 2031, driven mainly by checkpoint modulators, followed closely by T-cell engagers.

China offers the broadest therapeutic access with 74 approved agents available, significantly more than the 53 agents accessible in the US, while non-small cell lung cancer is the indication with the highest number of approved immuno-oncology treatments.

Personalized treatment using biomarkers, therapeutic options for checkpoint refractory patients, and the high cost of therapy remain as unmet needs.

Key Highlights

This report covers the eight major markets (8MM: US, France, Germany, Italy, Spain, the UK, Japan and China).
The report provides an overview of the current treatment options, pipeline products in development, as well as current and future R&D trends.
Key topics covered include a strategic competitive assessment of current and future drugs, unmet needs, KOL insights, and implications for the severe asthma market.
The base year of the sales forecast model is 2023, and the forecast period is 2023-2033.

Scope

This report covers the eight major markets (8MM: US, France, Germany, Italy, Spain, the UK, Japan, and China) includes the following topics -

Immuno-oncology (IO) overview
Trends
Classes of IO drugs - immune checkpoint modulators, bispecific T-cell engagers, cell therapy, cytokine therapeutics, cancer vaccines, and oncolytic viruses
Leading marketed and pipeline products
Market analysis
Regulatory landscape and market access
Opportunities, challenges, and unmet needs
Commercial assessment - major current and future players in the IO field

Reasons to Buy

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the global immuno-oncology therapeutics market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global immune-oncology therapeutics market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Product Code: GDHCHT618

1. Preface

1.1. Contents
1.2. Abbreviations
1.3. Related Reports

2. Executive Summary

3. Immuno-oncology Overview

3.1. What is IO?
3.2. What is IO According to Regulators?
3.3. Most Important Milestones of IO Development Globally
3.4. Key Chat on X

4. Trends

4.1. Industry Trends - Bispecific Antibodies
4.2. Industry Trends - Cancer Vaccines
4.3. Industry Trends - Cell Therapies
4.4. Industry Trends - Checkpoint Modulators
4.5. Industry Trends - Cytokines
4.6. Industry Trends - Oncolytic Viruses
4.7. Regulatory Trends

5. IO Classification

5.1. Industry Trends - Bispecific Antibodies
5.2. Bispecific Antibodies
5.3. Cancer Vaccines
5.4. Cell Therapies
5.5. Checkpoint Modulators
5.6. Next-generation Cytokines
5.7. Oncolytic Viruses
5.8. IO in Clinical Trials

6 Marketed Products

6.1. IO Marketed Products in the 8MM
6.2. Total Market Size for IO Agents
6.3. 10 Highest-Grossing IO Treatments in 2024
6.4. Leading Checkpoint Modulators in the 8MM
6.5. Leading T Cell Engagers in the 8MM
6.6. Leading Cancer Vaccines and Oncolytic Viruses in the 8MM
6.7. Leading Cell Therapies in the 8MM
6.8. Emerging IO Therapies

7 Pipeline Products

7.1. IO Pipeline Products in the 8MM
7.2. Future Outlook of IO Agents, According to High-Prescribing Physicians
7.3. Consensus Forecast Sales for the Top Three Pipeline Candidates per IO Class
7.4. The Forecast Highest-Grossing Bispecific Antibody Products
7.5. The Forecast Highest-Grossing Vaccine Products
7.6. The Forecast Highest-Grossing Cell Therapy Products
7.7. The Forecast Highest-Grossing Checkpoint Modulator Products
7.8. The Forecast Highest-Grossing Cytokine Products
7.9. The Forecast Highest-Grossing Oncolytic Virus Products

8. Market Analysis

8.1. Market Analysis and Forecast of the Six Classes of IO Agents
8.2. Top 10 Strategic Partnership Deals of the Last Decade by Size in the IO Space
8.3. Latest Strategic Partnership Deals in the IO Space
8.4. Top 10 Mergers and Acquisitions that Include IO Assets: 2020-2025
8.5. Latest Mergers and Acquisitions that Include IO Assets

9. Regulatory and Market Access

9.1. IO in Clinical Trials
9.2. Endpoints in IO Clinical Trials - KOL Perspective
9.3. Challenges in IO Clinical Trials - KOL Perspective
9.4. Regulatory and Market Access - US
9.5. Regulatory and Market Access - EU
9.6. Regulatory and Market Access - Japan
9.7. Regulatory and Market Access - China
9.8. Early Access Schemes
9.9. Barriers to Access According to High Prescribers

10. Opportunities, Challenges, and Unmet Needs

10.1. Bispecific Antibodies
10.2. Cancer Vaccines
10.3. Cell Therapies
10.4. Checkpoint Modulators
10.5. Cytokines
10.6. Oncolytic Viruses
10.7. Clinical Unmet Needs in IO - Gap Analysis
10.8. Commercial Unmet Needs in IO - Gap Analysis
10.9. Unmet Needs - KOL Perspective
10.10. Unmet Needs According to High Prescribers
10.11. R&D Strategies
10.12. Opportunities for the Industry - Modern Approaches & Collaboration
10.13. Closing Remarks - In Their Words

11. Companies

11.1. Drug Development Scorecard
11.2. Current Major Players - Novartis
11.3. Current Major Players - Merck & Co.
11.4. Current Major Players - Gilead Sciences
11.5. Current Major Players - Roche
11.6. Current Major Players - BMS
11.7. Current Major Players - AstraZeneca
11.8. Current Major Players - Sanofi
11.9. Current Major Players - Amgen
11.10. Current Major Players - Dendreon Pharmaceuticals
11.11. Current Major Players - Legend Biotech
11.12. Current Major Players - Johnson & Johnson
11.13. Current Major Players - Daiichi-Sankyo
11.14. Current Major Players - Kite
11.15. Current Major Players - Regeneron
11.16. Current Major Players - AbbVie
11.17. Future Players Based on Pipeline Strength - Genmab
11.18. Future Players Based on Pipeline Strength - Iovance Therapeutics
11.19. Future Players Based on Pipeline Strength - Replimune
11.20. Future Players Based on Pipeline Strength - CG Oncology
11.21. Future Players Based on Pipeline Strength - BioNTech
11.22. Future Players Based on Pipeline Strength - CRISPR Therapeutics
11.23. Future Players Based on Pipeline Strength - Allogene Therapeutics
11.24. Future Players Based on Pipeline Strength - Xilio Therapeutics
11.25. Future Players Based on Pipeline Strength - Candel Therapeutics
11.26. Future Players Based on Pipeline Strength - Oncolytics Biotech
11.27. Future Players Based on Pipeline Strength - Greenwich LifeSciences

12. Appendix

12.1. Sources
12.2. Primary Research
12.3. Key Themes Impacting the Pharmaceutical Industry
12.4. Our Thematic Research Methodology
12.5. About the Authors

Strategic Intelligence: Immuno-oncology (2025)

Description

Table of Contents

Key Highlights

Scope

Reasons to Buy

Table of Contents

Table of Contents

1. Preface

2. Executive Summary

3. Immuno-oncology Overview

4. Trends

5. IO Classification

6 Marketed Products

7 Pipeline Products

8. Market Analysis

9. Regulatory and Market Access

10. Opportunities, Challenges, and Unmet Needs

11. Companies

12. Appendix

13. Contact Us